retatrutide trial news Eli Lilly's Phase 3 Results: 28.7% Weight Loss | Drug Discovery & Development posted on the topic Demand for Unapproved Weight-Loss Drug

SKU: 11968209281

Pay in 4 interest-free payments of $5.75 Learn more

Live Spec

Demand for Unapproved Weight Loss Drug Surges on Social Media MedPage Today Use of an unapproved triple hormone receptor agonist bought online led to extreme side effects stemming from intractable diarrhea in a man who obtained the drug online from a direct to customer seller. The patient New Phase 3 retatrutide data just dropped Eli Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Great news again!!! A phase 2 trial of Retatrutide (TripleHormone Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% Trial of next gen weight loss drug retatrutide brings it one step closer to FDA approval Scientific American Phase III trials confirm benefits of Lilly's triple agonist retatrutide Drug Discovery World (DDW)

Store: psychwardcomics.com · Domain: psychwardcomics.com